English
Deutsch
Français
Nederlands
Español
Reset. Heal. Grow.
How Ayahuasca's Chemistry Actually Works: DMT, Harmine, and the Synergy Question
Here's a question I get from almost every first-timer I talk to: what exactly is in ayahuasca, and why does it work the way it does? Most people show up to a ceremony knowing the brew contains DMT and some kind of MAO inhibitor. That's about where the knowledge stops. And honestly, for a long time, that's about where the published science stopped too. But a growing body of pharmacology research has been quietly chipping away at the question. A systematic review published in the Brazilian Journal of Psychiatry pulled together sixteen studies on the chemistry of ayahuasca and tried to answer something deceptively simple: do these compounds just add to each other, or do they do something more interesting when they're combined? The answer matters — not just for chemists, but for anyone weighing whether to sit in ceremony with traditional brew versus the synthetic, isolated, or capsule-form alternatives now floating around the psychedelic landscape. Traditional ayahuasca is brewed from two plants: the vine Banisteriopsis caapi and the leaves of Psychotria viridis. The leaves carry N,N-dimethyltryptamine — DMT, the famously short-acting psychedelic that, taken on its own by mouth, does absolutely nothing. Your gut enzymes destroy it before it can reach your brain. That's where the vine comes in. B. caapi contains a family of compounds called beta-carbolines — primarily harmine, harmaline, and tetrahydroharmine (THH). These are reversible monoamine oxidase inhibitors, or MAOIs. They block the enzyme that would otherwise dismantle the DMT, allowing it to survive the trip through your digestive system and reach the receptors that produce the experience. Without the vine, the leaves are inert. Without the leaves, the vine is something else entirely — a purgative, a dream-inducer, a teacher plant in its own right according to the curanderos, but not the full ayahuasca experience. That much has been understood for decades. The harder question is what the harmala alkaloids are doing beyond protecting the DMT. And that's where things get interesting. Early work by McKenna and colleagues in the 1980s proposed that mixing the beta-carbolines together produced effects that were merely additive — basically, the sum of their individual MAO-inhibiting strengths. Neat, tidy, and a little boring. Later studies started complicating the picture. Researchers found that regular ayahuasca drinkers showed increased serotonin transporter binding sites on their platelets — a change that didn't appear in studies of DMT alone. Glennon's work in 2000 showed that harmala alkaloids themselves bind to 5-HT2 receptors, the same family of serotonin receptors DMT activates. So the vine isn't just a chaperone; it's nudging the same neurochemical machinery from a different angle. Then there's harmine on its own. A 2010 rat study found that chronic harmine administration produced antidepressant-like effects and raised levels of BDNF — brain-derived neurotrophic factor — in the hippocampus. BDNF is roughly the brain's fertilizer for growing new connections. A 2017 study went further and showed that harmine stimulated adult neurogenesis in cultured hippocampal cells. Meaning: harmine, alone, may help the brain grow new neurons. That's not what you'd expect from a molecule whose job description was supposed to be "keep DMT alive long enough to work." Human pharmacology studies have filled in more of the picture. Riba and colleagues found that ayahuasca produced significant activation in the frontal and paralimbic regions of the brain — the areas tied to emotional processing, self-reflection, and what neuroscientists call interoception, the felt sense of your own body. Brain imaging showed increased blood flow in the anterior insula, anterior cingulate, and the amygdala/parahippocampal complex. These are exactly the regions you'd want to engage if your goal is to confront stored trauma, examine ingrained patterns, or experience something like ego dissolution. Sampedro's 2017 work on the so-called psychedelic "afterglow" is one of the more striking findings in this whole literature. Participants showed measurable changes in brain chemistry and connectivity that persisted well after the acute experience ended. Reduced glutamate signaling in the posterior cingulate cortex. Increased connectivity between regions involved in self-awareness and emotional regulation. And — this is the part that matters for anyone considering a retreat — those neural changes correlated with increases in mindfulness traits like nonjudgmental awareness and self-compassion, and those traits were still elevated two months later. So when retreat-goers say something shifted in them and stayed shifted, they're not making it up. Something measurable is going on under the hood. You might be wondering why any of this pharmacology trivia should affect a decision about whether to drink the brew in a maloca in Peru. Fair. Here's why it matters in practical terms. The psychedelic industry is in the middle of a quiet identity crisis. Several biotech companies are working on synthetic alternatives — isolated DMT, harmine pills, time-released formulations, pharmahuasca capsules. The pitch is consistency, safety, and avoiding the rougher edges of the traditional brew (the nausea, the long duration, the variable potency). And there's a real case for that approach, especially in clinical contexts. But if the harmala alkaloids are doing more than just protecting DMT — if harmine alone is stimulating neurogenesis, if THH has its own SSRI-like activity, if the beta-carbolines are nudging serotonin receptors independently — then stripping the brew down to "just DMT plus an MAOI" might miss something important. The whole may genuinely be more than the sum of its parts. This is the part the curanderos have been saying all along, in their own language. The vine is a teacher. The leaf is a teacher. Together they teach something neither could teach alone. The pharmacology is starting to catch up to what indigenous practitioners have known for centuries. I don't think you need to memorize receptor names before you sit in ceremony. But a few practical takeaways are worth holding onto: Science on ayahuasca is still young. Most of these studies have small sample sizes. Some are in rats, not humans. The freeze-dried brew used in clinical trials isn't quite the same as what gets served on the second night of a Shipibo ceremony. And the synergy question — additive vs. truly synergistic — isn't fully resolved. The systematic review's authors are clear about this: there appear to be more synergistic mechanisms at work than current research can explain. Which is roughly where the curanderos have been pointing for centuries, if you ask them. The plants know things the pharmacology papers haven't gotten to yet. That doesn't make the science wrong — it just makes it incomplete, the way all science is incomplete on the way to better understanding. If reading this has made you more curious rather than less, that's probably the right response. A range of vetted ayahuasca ceremonies and plant-medicine retreats can be browsed on our marketplace here, and looking through them is a useful way to start translating the chemistry on the page into a concrete sense of where and with whom you might eventually sit. Take your time with the decision. The brew, after all, has been around for a very long time and will still be there when you're ready.
One-Day Ceremony or Multi-Day Ayahuasca Retreat: Which Is Right for You?
Here's a question that comes up in almost every conversation I have with someone considering ayahuasca for the first time: should I start with a single ceremony, or commit to a full retreat? It sounds like a logistics question. It isn't. The format you choose shapes almost everything else — how deep the work goes, how safe you feel, how well you integrate what surfaces, and whether the whole thing leaves you better off or just shaken up. I've sat in one-night ceremonies in a city apartment and seven-night retreats deep in the Peruvian Amazon. Both have their place. Neither is automatically better. What matters is matching the format to where you actually are — emotionally, physically, and in terms of what you're hoping plant medicine might help with. Let's walk through the real differences, because the marketing copy out there tends to skip the parts that matter most. A one-night ceremony usually runs from late afternoon into the small hours of the morning. You arrive, share a meal (or fast, depending on the tradition), receive the brew, and sit with the experience for four to six hours under the guidance of a facilitator or curandero. By sunrise you're usually home, or close to it. Simple in theory. In practice, it's a lot to fit into one night. For someone who's curious about plant medicine but not ready to spend a week away from work, kids, or daily life, this format has obvious appeal. It's also dramatically cheaper — a single ceremony in Europe or North America typically runs somewhere between 200 and 500 euros, while a week-long retreat in Peru can run anywhere from 1,500 to 4,000 dollars before flights. For people who've already done meaningful inner work elsewhere — therapy, meditation, breathwork — a single ceremony can serve as a check-in with the medicine rather than a full plunge. The catch? You get one shot. If the brew is mild that night, or if your body spends most of the ceremony purging rather than journeying, that's the experience you got. There's no second night to go deeper. And the morning after, you go back to your regular life with no buffer — no integration circle, no quiet day to process, no facilitator on hand if something difficult surfaces three days later. A proper retreat — let's say four to ten days — is a different animal entirely. You're typically looking at three to five ceremonies spaced over the course of the stay, with rest days, sharing circles, dietary support, and (in the better-run places) one-on-one time with the facilitators. The container itself becomes part of the medicine. Why does that matter? Because ayahuasca tends to reveal in layers. The first ceremony often shows you what needs attention. The second one starts working on it. The third or fourth is where things genuinely shift. Sitting with the same group of people through that arc, eating simple food together, going to bed at nine o'clock, walking in silence in the morning — all of it primes the nervous system in a way that a single Saturday night cannot. There's also the matter of integration support. Anyone who has worked with plant medicine seriously will tell you that the ceremony is maybe thirty percent of the work. The rest is what you do with what you saw. Good retreats build integration in: morning sharing circles, journaling time, gentle bodywork, conversations with the team about what surfaced and what to do with it. You leave with a thread you can keep pulling on. I'll be blunt here, because the gentle "it depends on your journey" framing isn't useful when you're actually trying to make a decision. That last point matters. Ayahuasca isn't a shortcut around the work — it's a magnifying glass held over it. People who try to skip preparation often end up with experiences that are confusing or destabilizing rather than helpful. People focus on the sticker price, but the real cost of plant medicine is wider than that. Here's what to actually budget for: When you add it all up honestly, a single ceremony might still come in cheaper, but the gap is smaller than it looks on paper. And the cost-per-insight, if you'll forgive that phrase, often favors the longer container. The format matters, but the people running it matter more. Whether you're considering a one-night sit or a ten-day retreat, ask these questions before you commit: If a place dodges any of these, walk away. There are plenty of careful, well-run options out there, and the wait for a good one is worth more than the convenience of a sketchy one. When someone asks me whether they should do a ceremony or a retreat, what they're often really asking is: am I ready, and is this going to help? Those are bigger questions, and only you can answer them. But I'd offer this: if you're drawn strongly enough to plant medicine that you've read this far, something in you already knows there's work to do. The format question is really about how much support you want around that work. My honest take, after sitting in plenty of both? If it's your first time and you're working with anything heavy — addiction, trauma, depression that hasn't shifted with conventional treatment — give yourself the longer container. The extra days are not a luxury; they're where the medicine actually has room to do what it does. If you're an experienced traveler in these waters and you just need a tune-up, a well-run single ceremony can be exactly right. For readers who want to explore further, a range of carefully vetted ayahuasca ceremonies and multi-day retreats can be browsed on our marketplace here. Take your time choosing — the right container is worth waiting for.
How Do Psychedelics Work? The Brain Science Behind the Trip
If you're researching a retreat, you've probably already read a hundred descriptions of what an ayahuasca night feels like. The visions. The purge. The crying, the laughing, the strange clarity at sunrise. What you've maybe not read — and what tends to matter once the romance fades and the booking deposit is staring back at you — is what these substances are actually doing in the brain that produces all of that. So let's get into it. Here's what the science currently says about how psychedelics work, in plain language, with the parts that are still guesswork clearly labelled as such. Whether you're considering ayahuasca for depression, psilocybin for stuck life patterns, or ibogaine for addiction, knowing the mechanism makes the experience less mysterious — and arguably safer to approach. The classical psychedelics — psilocybin (the active compound in magic mushrooms), DMT (the molecule that gives ayahuasca its punch), LSD, and mescaline (from San Pedro and peyote) — all share one core trick. They bind to a specific receptor in the brain called the 5-HT2A receptor. That receptor is normally the home of serotonin, the neurotransmitter that most people have heard of in the context of antidepressants. The psychedelic molecule shows up, fits the lock, and turns it — but it's not serotonin, and the neuron behaves differently as a result. Researchers have demonstrated this elegantly: give someone psilocybin alongside a drug called ketanserin, which blocks the 5-HT2A receptor, and the trip simply doesn't happen. No visuals, no ego dissolution, no insight. The molecule is still in your bloodstream. It just has nowhere to land. This is also why some psychedelics hit harder than others. LSD binds to the 5-HT2A receptor extremely tightly, which is part of why a microscopic dose produces a twelve-hour experience. Mescaline has additional dopamine receptor activity, which is part of why a San Pedro ceremony feels different from a psilocybin one — warmer, more embodied, less reality-shattering. Here's the finding that got the research world genuinely excited over the past decade. Psychedelics promote neuroplasticity — the brain's ability to physically rewire itself, growing new branches between neurons and forming new circuits. Why does this matter for someone considering a retreat? Because depression, addiction, and chronic anxiety appear to involve a kind of structural shrinkage in the brain. In depression specifically, the little branching extensions of neurons in the prefrontal cortex — the area that regulates mood and emotional response — literally wither. The neural architecture for flexible thinking and steady mood gets sparse. You stay stuck in the same grooves. Lab studies have shown that LSD and DMT cause those branches to regrow. In some experiments, the growth was more pronounced than what ketamine produces, which is notable because ketamine is already considered a breakthrough treatment for stubborn depression. Block the 5-HT2A receptor and the neuroplasticity vanishes too — same receptor, multiple effects. The practical takeaway: a single psychedelic experience may open a window of roughly two to four weeks during which the brain is unusually pliable. This is the integration window that experienced facilitators talk about. The substance does the chemistry; what you do in those weeks — therapy, journaling, ceremony, the hard conversations, new habits — is what carves the new grooves. Skip the integration and you've largely wasted the chemistry. The researcher Robin Carhart-Harris proposed something called the entropic brain hypothesis around a decade ago, and it's held up surprisingly well. The idea borrows from physics. Entropy is a measure of disorder, of unpredictability, of how many possible states a system can be in. Carhart-Harris and his team scanned people on LSD and psilocybin and found that brain activity becomes more entropic — less predictable, less locked into the familiar grooves. Normally-segregated brain regions start chatting with each other. The default-mode network, which is the chatterbox of the self, the inner narrator constantly running commentary about who you are and what people think of you, goes quiet. Without it, the boundary between self and not-self can blur. That's the famous ego dissolution. Carhart-Harris's framework places ordinary waking consciousness in a middle zone: If you accept this framing, depression and addiction look less like chemical imbalances and more like ruts. Psychedelics shake the system out of its rut by temporarily injecting chaos. The lasting benefits — increased openness, less rigid thinking, better ability to break habits — may come from that shake-up. Worth noting: this same mechanism is why bad sets and bad settings produce bad trips. A chaotic brain in a chaotic environment with unprocessed trauma in the room is not a peaceful evening. A 2019 study put participants in an EEG and measured what DMT — the same molecule that makes ayahuasca what it is — does to the brain's electrical rhythms. The findings explain a lot. Alpha waves, the brain rhythm associated with relaxed wakefulness, dropped sharply. Delta and theta waves, which dominate during dreaming, surged. In other words, the waking brain temporarily started running the same software it uses when you're deep in REM sleep, except the lights were on and the person was alert. The lead researcher described it as “dreaming with your eyes open,” which matches what people report after a strong DMT or ayahuasca experience almost word-for-word. This helps explain why ayahuasca visions feel so much more vivid and meaningful than ordinary imagination. You're not picturing things. You're dreaming things, in the same neurological sense as a sleeping dream, while conscious enough to engage with them and remember them. Back in 1954, Aldous Huxley took mescaline and wrote The Doors of Perception. He borrowed an idea from the philosopher C.D. Broad: the brain, Broad argued, doesn't create consciousness so much as filter it. There's more sensory and mental information available at any moment than you could possibly use, so the brain runs a reducing valve that narrows the firehose down to a manageable trickle. You see what helps you survive and ignore the rest. Huxley's claim was that psychedelics temporarily loosen the valve. More gets through. Colours, meanings, connections, memories, sensations the brain ordinarily suppresses as irrelevant. For seventy years this was a poetic metaphor. Then neuroimaging caught up. When researchers first scanned people on psilocybin, they expected to see more brain activity. Instead, certain hub regions — particularly the default-mode network — went quieter. With the filter dialled down, suppressed material can flood the conscious mind. This is, mechanistically, why people on ayahuasca recover memories they'd forgotten, see connections they'd missed, and confront emotional content they'd been managing to avoid for decades. None of this is academic if you're trying to decide whether to fly to Peru, Costa Rica, or the Netherlands and drink something that will rearrange your nervous system for a night. A few practical implications follow from the science: The science doesn't make psychedelics magic and it doesn't make them safe by default. It makes them a tool — a powerful one, increasingly well-understood, with a mechanism of action that genuinely lines up with the experiences people have been describing for thousands of years. The Amazonian shamans who built ayahuasca traditions didn't know about 5-HT2A receptors. They knew the medicine showed people what they'd been hiding from themselves. Turns out those are two ways of describing the same thing. If reading this has made you more curious rather than less, the next step is to look closely at specific retreats — their facilitators, their screening processes, their integration support — and find one that matches what you're actually after. A curated selection of ayahuasca and psychedelic plant-medicine retreats can be browsed on our marketplace here. Take your time with the decision. Whatever the brain is doing under these molecules, it deserves a thoughtful container around it.
What Is Vipassana Meditation? Origins, Practice, and Honest Caveats
Vipassana is the kind of practice people whisper about at retreat centers — the one your friend disappeared into for ten silent days and came back vaguely different. Two and a half thousand years old, taught by the Buddha himself, and still strangely intact after all that time. If you've been circling the idea of sitting a course, or you're just curious why anyone would voluntarily stay silent for over a week, it helps to understand what Vipassana actually is before you commit. This is a contemplative technique, not a plant medicine — worth saying upfront. There's no substance involved, no facilitator pouring you a cup of anything. Just you, your breath, your body, and a lot of time to notice what's going on inside both of them. That said, plenty of people who eventually find their way to ayahuasca or psilocybin retreats started with sitting practice. The two worlds share more terrain than you might think. The word Vipassana translates roughly as “seeing things as they really are.” It traces back to Gotama the Buddha around 528 BCE, who spent the last forty-five years of his life teaching it as a path out of suffering. For about five centuries it spread across India, peaking during Emperor Asoka's reign in the third century BCE. Then, as these things go, it largely vanished from the country of its birth. What kept it alive was a quiet chain of teachers in Myanmar. Generation after generation, they preserved the technique while it faded elsewhere. The modern revival owes most of its momentum to S.N. Goenka, a Burmese-born businessman of Indian descent who trained under Sayagyi U Ba Khin and began teaching in 1969. Goenka's gift was making the practice accessible without stripping its depth — he framed it as a secular, universal tool rather than a religious requirement. That framing is why you can walk into a Vipassana center today without subscribing to any particular faith. The Theravada Buddhist tradition still holds Vipassana as a central practice, but the courses Goenka's network offers are deliberately non-sectarian. You'll hear chanting on recordings. You won't be asked to convert to anything. If you've ever used a meditation app, you've probably done some version of śamatha — calming, breath-focused mindfulness. Sit, follow the breath, notice when the mind wanders, come back. It's foundational, and it works. Most people benefit enormously from it. Vipassana takes that foundation and adds something specific: a slow, systematic scan of the body, paying close attention to whatever sensation arises — itch, ache, warmth, tingle, numbness — without reacting to it. Where śamatha says let the thought pass like a cloud, Vipassana says sit with the sensation underneath the thought and watch it change. You're not analyzing. You're not narrating. You're observing the raw data of being in a body, and you're learning that every sensation, pleasant or excruciating, eventually shifts on its own. The technical name for this is equanimity toward impermanence. The practical name is: you stop flinching at your own life quite so much. Cravings get less sticky. Aversions get less sharp. The story your nervous system has been telling itself about what's tolerable starts to loosen. The standard introduction to Vipassana in the Goenka tradition is a ten-day residential course. They're offered worldwide and run on donations — no fee for first-time students. That generosity isn't a marketing hook; it's structural. Past students who got something from the course fund the next batch. Here's the honest version of what you sign up for: Days three and four are when most people hit the wall. The knee pain becomes biblical. The mind generates elaborate fantasies about quitting, leaving, finding the nearest pizza. People do leave. Most stay. By day seven, something shifts — not always pleasant, but undeniably real. By day ten, when silence breaks, you'll watch a roomful of strangers fumble awkwardly back into language and realize you've all just been through something together that none of you can quite describe. This is the question worth sitting with — pun fully intended — before you book anything. Vipassana is not a wellness vacation. It's not a spa. It's not particularly gentle. It can surface trauma, grief, rage, and material you've been successfully avoiding for decades. For some people, that's exactly the medicine. For others, it's the wrong tool at the wrong time. Vipassana tends to suit people who: It can be a poor fit, or actively harmful, for people in acute psychiatric crisis, those with untreated severe PTSD, or anyone who interprets ten days of forced introspection as a kind of test they need to pass. The centers screen for some of this, but not all of it. Be honest on the application. If a therapist is helping you stay upright right now, talk to them first. A lot of readers find their way to silent meditation after a psychedelic experience cracks something open and they realize they need a sustainable practice to integrate it. The reverse also happens — long-time meditators eventually become curious about whether ayahuasca, psilocybin, or another master plant might show them something their cushion has been pointing at for years. The traditions aren't competing. They're doing different jobs. Psychedelics tend to dissolve; meditation tends to refine. A weekend ayahuasca retreat can hand you an insight in eight hours that you wouldn't have stumbled into on your own in eight years — but you still have to live with that insight, embody it, and not let it evaporate. That's where sitting practice earns its keep. Conversely, a daily meditation practice without occasional rupture can become its own kind of comfortable rut. If you're someone weighing both paths, you don't have to choose. Many of the most grounded facilitators in the plant-medicine world have decades of silent retreat behind them. The skills transfer. If a full ten-day course feels like jumping off a cliff, start small. Twenty minutes a day for a month will tell you a lot about whether the technique resonates. Find a quiet spot — a corner of the bedroom, a chair by a window, even (genuinely) the bathroom if that's your only privacy. Sit cross-legged on a cushion or upright in a chair with both feet on the floor. Close your eyes. Spend the first few minutes following the breath at the nostrils. Then begin slowly scanning attention from the crown of your head down to your toes, lingering on each small area, noticing whatever sensation is there — or noticing the absence of sensation, which is also data. Don't try to feel anything in particular. Don't congratulate yourself when something pleasant arises or recoil when something uncomfortable does. Just watch. When the mind wanders, bring it back to wherever you were on the body. Begin again. That's the whole instruction. You'll be bad at it. Everyone is. The badness is the practice. If something in this stirs your curiosity and you want to explore the wider landscape of contemplative and plant-medicine work together, a range of integration-focused and meditation-adjacent retreats can be browsed on our marketplace here. Whatever path you choose, the willingness to sit honestly with your own mind — for ten days or twenty minutes — is the part that actually changes things.
Is Ayahuasca Legal? A Country-by-Country Look for Retreat-Seekers
You've been reading about ayahuasca for months. Maybe years. You've watched the documentaries, listened to the podcasts, and you're starting to seriously consider booking a retreat. Then a practical question lands: is ayahuasca legal? It's the right thing to ask before you spend money on a flight, and the honest answer is more complicated than yes or no. Here's the short version: the legal status of ayahuasca depends on where you are, who's serving it, and how a particular government chose to interpret a few decades-old drug treaties. The longer version — the one that actually helps you make a decision — is below. The active ingredient that gives ayahuasca its psychedelic punch is DMT (N,N-dimethyltryptamine), which most Western countries classify as a Schedule I or equivalent prohibited substance. That puts it in the same legal bucket as LSD and psilocybin — substances that were criminalised after the counterculture boom of the late 1960s. Here's where it gets interesting. The 1971 UN Convention on Psychotropic Substances, the treaty most countries built their drug laws around, controls the molecule DMT itself — not the plants that contain it. The ayahuasca brew is made from two plants: the Banisteriopsis caapi vine, which contains MAO inhibitors that let DMT survive your digestive system, and Psychotria viridis (chacruna), whose leaves are loaded with DMT. Neither plant is on the international schedule. So in many jurisdictions, growing or possessing the raw plants exists in a hazy in-between. The moment you brew them together and the tea contains DMT, you've technically crossed into illegal territory. Different countries have interpreted this gap in very different ways, which is why a global map of ayahuasca legality looks like a patchwork quilt. Possessing B. caapi or chacruna leaves on their own isn't illegal in most of North America. Brewing them into a tea that contains DMT is. That's the line, and federal authorities in both countries have prosecuted people for crossing it. There's one well-established exception: religious freedom. Two Brazilian-rooted churches, the União do Vegetal (UDV) and Santo Daime, have fought and won court battles affirming their right to use ayahuasca as a sacrament. The UDV's 2006 Supreme Court victory in the US is the landmark case. These congregations are not casual drop-in ceremonies — they're serious religious communities with screening processes, ongoing membership, and a doctrinal framework. If you want a sustainable, fully-legal way to sit with ayahuasca in the US or Canada, joining one of these churches is the cleanest path. Beyond the churches, there's a quiet underground. Search around in any major city — New York, Los Angeles, the Bay Area, Toronto, Vancouver — and you'll find ceremonies running. They exist in legal shadow, and participants and facilitators carry real risk. The recent psilocybin decriminalisation in cities like Denver, Oakland, and across Oregon and Colorado suggests that the wider policy landscape is shifting, but ayahuasca specifically hasn't been folded into those reforms yet. This is the part of the map where things relax. In the countries where ayahuasca has been used ceremonially for centuries, it's protected, legal, or simply uncontested. If you want to do this with the fewest legal complications and the deepest traditional roots, Latin America is the answer. The trade-off is the obvious one: international travel, vaccination considerations, the need to vet centres carefully because the region also has its share of poorly-run operations and outright bad actors. Europe is the patchwork within the patchwork. The picture shifts every couple of years as test cases move through national courts. Spain has historically been the most permissive — there's no specific statute outlawing ayahuasca, and prosecutions are rare. Itinerant curanderos often base themselves there and travel to other countries for ceremonies. Portugal, which decriminalised personal drug use across the board in 2001, also tends toward leniency. Italy has seen mixed rulings. The Netherlands, once the friendly grey-zone destination for European seekers, tightened its stance and now treats ayahuasca more strictly — a change that affected Santo Daime communities operating there. The UK takes a harder line. DMT is a Class A controlled substance, and possession of brewed ayahuasca has led to prosecutions. Despite that, ceremonies do happen quietly across the country. France and Germany are similarly restrictive on paper, though enforcement varies. If you're in Europe and want clear legal footing, Spain is your most relaxed option. For anywhere else on the continent, you're working in a zone where the law is real but inconsistently applied. In Australia, DMT is Schedule 9 — prohibited. Growing the caapi vine itself isn't illegal, but the brew is. Prosecutions for personal ceremonial use are rare, and an underground retreat scene exists. New Zealand takes a similar position. Across parts of Southeast Asia, ayahuasca ceremonies happen relatively openly in places like Bali and parts of Thailand, often imported by Western facilitators serving the wellness-tourism circuit. The legal status is unclear rather than explicitly permitted, and the picture can change quickly with a single high-profile case. If you're considering a retreat in this region, ask hard questions about who's running it and how long they've been operating. Legal risk is one layer. Physical and psychological risk is another, and the two get conflated more than they should. Pure ayahuasca, served well, has a surprisingly clean safety profile compared to many legal pharmaceuticals. But there are real contraindications you need to take seriously: A good retreat will screen you carefully. If a centre takes your booking without asking about medications, medical history, and mental-health background, that's a red flag worth walking away from. The practical question for most readers isn't really "is ayahuasca legal" — it's "what level of legal and personal risk am I willing to accept, and where does that point me?" There are three honest paths: The fully-legal path: Join a recognised UDV or Santo Daime congregation in your home country, or travel to Peru, Brazil, Ecuador, Colombia, or Costa Rica where the medicine has clear legal and cultural standing. This is the option I'd recommend to almost anyone serious about the work. The traditional context adds something that an underground ceremony in someone's apartment simply can't replicate. The grey-area path: book a retreat in a jurisdiction where the law is murky but enforcement is rare — parts of Europe, certain pockets of Asia. The legal risk is real but small if you're discreet and the centre is established. The underground path: the highest risk, the lowest accountability, and the option where most of the documented harms in the ayahuasca world have happened. I'd think very hard before going this route. Whichever path you choose, do your homework on the facilitator. Years of experience, training lineage, how they handle medical screening, what integration support looks like after — these matter far more than the legal label. A legal ceremony with a careless facilitator can hurt you more than a grey-area ceremony with a careful one. If you're at the stage where you're ready to compare specific centres rather than read more theory, a curated selection of vetted ayahuasca retreats can be browsed on our marketplace here. Take your time with the decision — this is the kind of journey that rewards patience and punishes haste.
Craving More Stories?
Join our ShopAyahuascaRetreats newsletter for the latest updates on thrilling
destinations and inspirational tales, delivered straight to your inbox!
We value your privacy. Your email address will never be shared or published.
Sexual Abuse in Ayahuasca Ceremonies: What a Major Survey Revealed
Nobody wants to start a conversation about ayahuasca with the word abuse. The brew is sacred to the people who carry the tradition, and life-changing for many who sit with it. But if you're weighing whether to fly to Peru or Costa Rica and hand your nervous system over to a stranger in the dark, the most useful thing a writer can do is tell you the truth — including the parts the glossy retreat brochures skip. A few years back, a community-led survey took on exactly this taboo. The findings are sobering, occasionally hopeful, and genuinely useful for anyone considering an ayahuasca retreat. I want to walk you through what came back, what it means for your decision, and how to use the information without either dismissing plant medicine or romanticising it. For years, whispers circulated through the plant-medicine world about facilitators crossing lines — touching participants inappropriately during ceremony, soliciting sexual contact under the guise of healing, taking advantage of people in deeply altered states. Some stories made it to journalism. Most didn't. The combination of remote jungle settings, language barriers, power asymmetry, and the assumption that a shaman is somehow above reproach made it remarkably easy for misconduct to go unreported. In response, a working group within the broader ayahuasca community drafted a free, downloadable safety guide — translated into fourteen languages and distributed across retreat centres, tour agencies, and tourism offices in Peru. The companion legal resource breaks down, country by country, what your rights are if something happens in Peru, Brazil, Costa Rica, Bolivia, or Mexico. By early 2023 the guide had been downloaded nearly 29,000 times. That's not a niche document. That's a quiet movement. The survey came next. Launched in 2020 in English and Spanish, it asked a simple question: are people in the community aware that this happens, and is the safety guide actually changing how they behave? Out of 2,071 people who started the survey, 745 completed it in a way that allowed their answers to be analysed. The drop-off is normal for online surveys, especially on sensitive subjects — some people don't have skin in the game, some find the questions uncomfortable and bail. Of those who finished, roughly 60% identified as female, 38% as male, and the rest as something else. Here's the figure that stopped me when I first read it: 83.1% of respondents already knew that sexual abuse can and does occur in ayahuasca settings. Only 16.9% had no idea. That's a community that has, at least at the level of awareness, accepted there's a problem. More uncomfortable: 52.1% had direct or indirect experience with sexual misconduct in these settings. Either it had happened to them, to someone they knew, or they'd heard credible accounts of it happening to others. About half. Let that sit for a second. The pattern of what people reported is worth understanding. The more covert behaviours — verbal sexual advances, hands lingering where they shouldn't, the ambiguous touch a facilitator might brush off as healing work — turned up far more often than overt sexual assault or rape. That's consistent with what we know about predatory behaviour generally. It rarely starts with the worst-case act. It starts with small boundary tests, in a setting where the person being tested is too altered, too disoriented, or too culturally deferential to push back. Around 94% of respondents said the guide gave them clear, helpful examples of what abuse in these settings can look like. That's a strong response to an educational document. More interesting is the behaviour question: 32.8% said reading the guidelines actually changed how they approach ayahuasca ceremonies. If a third sounds modest, consider what's being measured. A consultant in the sexual-violence field noted that in forensic psychology, even a 5% behavioural shift from an intervention is considered significant. Getting a third of respondents to admit — in writing, on a survey about a taboo subject — that they're doing things differently is, by the standards of the field, a serious result. The 169 people who wrote in their own words about what changed gave us the most useful map. Here's roughly how the themes shook out, in order of how often they came up: A small but striking group — about 4 out of 130 — said the guidelines made them question whether they wanted to do ayahuasca at all. That's a legitimate response to honest information. Not every reader of this article should book a retreat. Some shouldn't. You're probably here because something in your life feels stuck — addiction, depression, trauma, a pattern you can't seem to break — and ayahuasca keeps coming up in your reading. That's a real and valid reason to be looking. Plant medicine has helped a lot of people. It has also been the setting for harm. Both things are true. The job is to filter for centres that take the second part seriously. From the survey and from my own time reporting on this, here's what to actually look for when you're vetting a place: One of the more thoughtful responses in the survey came from people who'd started seeing shamans as humans rather than gods. That reframe matters. The plant itself doesn't care about your money or your status. The human pouring it for you might. Cultural reverence is a beautiful thing, and it's also exactly the dynamic predators exploit. You can hold deep respect for a tradition while still treating any individual practitioner as a person who needs to earn your trust. Bringing a friend is underrated. So is staying somewhere with other participants you can talk to between ceremonies. Isolation is the abuser's friend. A buddy who'll notice if something seems off — and who'll back you up if you need to raise a concern — is one of the most effective safety measures available, and it costs nothing. And one more thing the survey hinted at but didn't quite name: integration matters here too. If something happens that doesn't sit right, you need somewhere to bring it. A therapist who knows about psychedelic experiences, a trusted integration circle, a friend who'll listen without trying to fix it. Don't sit alone with a confusing memory for months. That's how harm calcifies. The point of all this isn't to scare you away from ayahuasca. Plenty of people have profound, safe, transformative experiences every week. The point is to make you a harder target — informed, skeptical of the right things, and clear about what a reputable container looks like. The community is, slowly, getting better at this. The survey itself is evidence of that. Awareness is up. Conversation is up. Some behaviour is genuinely changing. If you've read this far and you're still drawn to the work, take that seriously — both the pull and the responsibility to choose well. For readers who want to take this further, a range of vetted ayahuasca retreats can be browsed on our marketplace here. Read carefully, ask the hard questions, and trust your gut when something feels wrong. The medicine will still be there once you've found the right place to meet it.
Psychedelics for Depression and Addiction: What the Research Actually Shows
Picture a quiet room in Manhattan. A low brown couch, a small Buddha statue, hand-painted dishes on a side table. It looks like someone's grandmother's living room from 1974. It is, in fact, the setting where some of the most surprising mental-health research of the last decade has unfolded — a place where cancer patients have swallowed a capsule of psilocybin and walked out hours later describing the experience as one of the most meaningful of their lives. This is the strange, hopeful frontier of psychedelics and psychedelic-assisted therapy. After decades of being treated as cultural contraband, substances like psilocybin, ayahuasca, ibogaine, and MDMA are being studied seriously again — and the early data on depression, anxiety, and addiction is hard to ignore. If you've found your way here because you're quietly wondering whether plant medicine might help with something you've been carrying for years, you're not alone. A lot of people are wondering the same thing. The reason scientists keep using words like “breakthrough” and even “surgical intervention” when they talk about psychedelics isn't hype. It's that a single dose, given in the right setting with trained support, seems to do what years of daily SSRIs sometimes can't — particularly for people stuck in the deepest grooves of despair. In one well-known trial at NYU and Johns Hopkins, cancer patients with severe end-of-life anxiety were given psilocybin alongside therapy. The majority reported sustained relief from depression and existential dread months later. Not a slight improvement. A genuine shift. Many of them ranked the experience among the top five most meaningful events of their entire lives — comparable to the birth of a child or the death of a parent. That's an unusual thing to hear from a clinical trial. Pharma research doesn't usually produce results that read like a memoir. Here's a way to think about depression that helped me understand why psychedelics seem to do what they do. Imagine your brain as a city, full of roads. Some are well-worn highways used a thousand times a day — your habitual thoughts, your self-criticism, your story about why you're not enough. Other roads are barely paved, rarely traveled. In a depressed brain, the highway traffic gets stuck. Rush hour, all day, every day. Researchers at Imperial College London have shown that psychedelics appear to do something genuinely strange — they reduce traffic on the overused routes and send neural activity skittering down the empty ones. Connections form between regions of the brain that normally don't talk to each other. The cogs, as one researcher put it, get loosened. That loosening is often what people describe afterward. The rumination quiets. The sense of being trapped inside one narrow story about yourself softens. For a few hours, the mind escapes the rut — and sometimes, the new perspective sticks. The addiction research is where things get especially interesting. Addiction, like depression, is partly a story of stuck patterns — the same circuits firing, the same craving, the same coping behavior on repeat. Substances like ayahuasca, ibogaine, and psilocybin appear to interrupt those loops, sometimes dramatically. Ibogaine, derived from the iboga root of West Africa, has the longest underground reputation for treating opioid dependence. People who've gone through ibogaine treatment often describe a long, difficult inner journey — sometimes 24 to 36 hours of intense visions — followed by a striking reduction in withdrawal symptoms and cravings. It's not magic, and it's not without serious cardiac risks that require medical screening. But for people who've tried everything else, it's often the first thing that's actually worked. Ayahuasca, the Amazonian brew built around the Banisteriopsis caapi vine, has a different shape but a similar effect on certain people. The ceremonies are long, communal, and held by experienced facilitators in traditions that stretch back generations. Many participants come specifically because of addiction — to alcohol, to cocaine, to the quieter addictions of overwork and self-loathing — and leave with a fundamentally different relationship to whatever they were running from. The category of plants and brews used this way is sometimes called the master plants: teachers in the Amazonian sense, not chemicals to be consumed casually. That framing matters, because it shapes how the experience is approached — with preparation, respect, and a willingness to actually listen to what surfaces. This is the question almost everyone researching a retreat wants answered honestly, so let's be honest. A psychedelic ceremony — whether it involves ayahuasca, psilocybin, or San Pedro — is not a euphoric night out. It can be uncomfortable. It can be physically demanding. With ayahuasca specifically, vomiting (called la purga) is common and considered part of the healing. People often describe an initial wave of fear or disorientation. One man I spoke with, a sailor who'd done a Johns Hopkins psilocybin trial, compared the early part of his experience to falling off his boat in open ocean — looking back and finding the boat gone, then the water gone, then himself gone. Terrifying, in the moment. He came through it, with help from his facilitators, into something he still can't quite describe — a sense of being witness to life itself, free from the constant management of being a self. That arc — through difficulty, into something larger — is common. It's why a good retreat isn't just about the medicine. It's about who's holding the space. If you're considering a retreat, this is where to spend your attention. The medicine matters less than the container around it. Here's what experienced facilitators and seasoned participants tend to look for: One more thing: be skeptical of anyone who promises outcomes. Real facilitators talk about possibilities and risks. Sales pitches talk about transformation guaranteed. It depends entirely on where you are and what plant you're talking about. In the United States, psilocybin is federally illegal but decriminalized in cities like Denver, Oakland, and parts of Oregon, where supervised therapeutic use is now permitted under state law. Ayahuasca is federally illegal except for specific religious exemptions granted to the União do Vegetal and Santo Daime churches under a 2006 Supreme Court ruling. Outside the U.S., the landscape opens up. Peru, Costa Rica, the Netherlands, Jamaica, Mexico, and Brazil each host legal or tolerated retreat scenes for various plant medicines. Most serious retreat-seekers end up traveling, both for legal reasons and because the lineages are stronger where the plants come from. Plant medicine isn't for everyone. People with personal or family histories of schizophrenia, bipolar disorder, or psychotic episodes are generally advised to avoid classical psychedelics. Certain heart conditions rule out ibogaine. SSRI users typically need to taper off well before drinking ayahuasca, under medical guidance. And then there's the harder caveat: a single ceremony, no matter how profound, isn't a cure. It's a doorway. Whatever you see inside still has to be carried back into your daily life — your relationships, your work, your habits. The people who get the most lasting benefit are almost always the ones who do the integration work afterward, often with a therapist who understands psychedelics. For readers who want to take this further, a range of curated ayahuasca and plant-medicine retreats can be browsed on our marketplace here. Whatever you decide, take your time with the decision — this is one of those choices that rewards patience and punishes impulse.
Mushrooms and Brain Health: Can Psilocybin and Functional Fungi Help Prevent Alzheimer's?
Watching a parent forget your name is a particular kind of grief. It arrives in pieces, over years, and by the time you understand what's happening, the person you knew has already started to fade. For families with a history of Alzheimer's, that grief tends to carry a second weight — the quiet question of whether the same thing is waiting for them. That question is fueling one of the more interesting corners of the current psychedelic and plant medicine conversation: the role of mushrooms — both the functional kind like Lion's Mane and the psychedelic kind like psilocybin — in supporting long-term brain health. It's a thread that runs from cutting-edge neuroscience labs to grandmothers microdosing in suburban kitchens, and it's worth pulling on if you're someone trying to protect your mind for the decades ahead. The standard medical answer to Alzheimer's has, for decades, been a shrug dressed up in a lab coat. A few drugs slow symptoms modestly. None reverse the disease. And the cruel structural problem is this: by the time symptoms appear, the underlying damage has been building quietly for twenty or thirty years. If you want to do something useful, you have to start long before anything feels wrong. That timeline is what's pushed a lot of curious, science-literate people toward mushrooms. Functional varieties — Lion's Mane, reishi, cordyceps, chaga — have been used in East Asian medicine for centuries. Lion's Mane in particular has caught researchers' attention because of compounds called hericenones and erinacines, which appear to stimulate nerve growth factor in the brain. In plain English: they may help neurons grow and stay connected. That's exactly the machinery Alzheimer's destroys. Then there are the psychedelic mushrooms, which work on a different but related axis. Psilocybin, the active compound in magic mushrooms, has been shown in early studies to promote neuroplasticity — the brain's ability to rewire itself and form new connections. Researchers at Johns Hopkins and Imperial College London have spent the past several years documenting how a single high dose can reset patterns of depression that have resisted every other treatment. The implications for cognitive aging are still being studied, but the early signals are interesting enough that serious money and serious scientists are paying attention. This trips people up, so it's worth being clear. Not all medicinal mushrooms get you high. In fact, most don't. Both categories are mushrooms. Both are being studied for brain benefits. But they work through very different mechanisms and demand very different commitments from the person taking them. Functional mushrooms are a daily habit, like a vitamin. Psychedelic mushrooms — taken at ceremony doses — are an event you prepare for, integrate from, and don't take lightly. Microdosing has gone from Silicon Valley curiosity to something your aunt might be doing. The basic idea: take a sub-perceptual dose of psilocybin (usually around a tenth of a recreational dose) on a schedule — say, every third day for a few weeks — and observe what happens. People report sharper focus, lifted mood, reduced anxiety, and a softer relationship to old mental ruts. Veterans use it for PTSD. Mothers use it for the relentless cognitive load of parenting. Older adults are starting to use it specifically with brain longevity in mind. The research here is genuinely early. Placebo effects are real, dosing isn't standardized, and most of what we know comes from self-reports rather than controlled trials. That said, the consistency of those reports across very different populations is hard to dismiss entirely. Companies and academic labs are now running proper studies to figure out what's signal and what's noise. If you're considering microdosing, a few honest cautions: legality varies wildly by where you live, dosing without scales and proper sourcing is a recipe for inconsistent experiences, and microdosing isn't appropriate for people with certain mental health conditions or on certain medications. It is not a magic bullet. It is, at best, one tool in a much larger toolkit. Here's the part the supplement industry would prefer you skip. Mushrooms — functional or psychedelic — are not going to save a brain that's being neglected in every other way. The boring stuff still matters more than anything in a capsule. Mushrooms slot into this picture as a possible enhancer, not a replacement. The person taking Lion's Mane while sleeping four hours a night and living on takeout is not going to outrun their genetics. For some people, the entry point isn't a daily supplement but a single, carefully held psychedelic experience — often within the container of a retreat. Psilocybin retreats in legal jurisdictions like the Netherlands, Jamaica, and increasingly parts of the U.S. offer multi-day programs where participants prepare, journey under supervision, and integrate what came up afterward. Ayahuasca retreats in Peru, Costa Rica, and elsewhere offer something related but distinct — a longer, often more challenging plant medicine arc with deep indigenous roots. Why would someone worried about Alzheimer's consider this? A few reasons. The neuroplasticity window opened by a full psychedelic experience appears to last weeks, not hours. The psychological work that often happens — releasing long-held grief, untangling patterns of depression, reconnecting with purpose — has its own protective effect on the aging brain. And for people with a strong family history, the experience of facing mortality directly, which most ceremonies provoke in one form or another, tends to clarify priorities in ways that change everyday behavior. None of this is a guarantee. Retreats vary enormously in quality, screening, and safety, and the wrong setting can do more harm than good. If you're exploring this path, vet facilitators carefully, be honest about medications and medical history, and pay attention to whether the program treats integration as seriously as the ceremony itself. For readers who want to explore this further, curated psilocybin and plant medicine retreats can be browsed on our marketplace here. The science of mushrooms and brain health is real, promising, and nowhere near settled. Lion's Mane and other functional mushrooms have a plausible mechanism and a long traditional track record. Psilocybin has produced some of the most striking results in modern psychiatry. Microdosing is interesting and under-studied. None of it is a substitute for sleep, movement, diet, and human connection — and none of it can rewind damage that's already done. But for someone in their thirties, forties, or fifties watching a parent disappear into Alzheimer's, the question isn't whether mushrooms are a miracle. It's whether the accumulated weight of small, intelligent choices made over decades can shift the odds. The current evidence says yes, probably, and that fungi — humble, ancient, and increasingly well-studied — deserve a real seat at that table.
Iboga and Ibogaine: What an Honest First Retreat Actually Looks Like
The first thing anyone who has sat with iboga will tell you is that it doesn’t feel like the other plant medicines. Ayahuasca moves like a river. Psilocybin opens like a door. Iboga sits you down in a hard chair, switches on a projector, and walks you through your own life — frame by frame — without much sympathy and without much hurry. If you’re researching an iboga or ibogaine retreat because something in your life has stopped working — an addiction you can’t shake, a depression that won’t lift, a grief you can’t name — it’s worth understanding what you’d actually be signing up for. This isn’t a glamour piece. Iboga is one of the most physically demanding psychedelics and plant medicines a person can take, and it’s also one of the most effective tools we currently know of for breaking certain kinds of addiction. Both of those things are true at once. Let’s get into what that really means. Iboga is the root bark of Tabernanthe iboga, a shrub native to the equatorial forests of Gabon and the surrounding region. In Bwiti tradition — the spiritual practice that has used iboga for centuries — it’s considered a master plant and a teacher, not a party drug or a quick fix. Ceremonies are long, sober, and structured. They’re also nothing like an ayahuasca ceremony, even though both fall under the broad banner of plant medicine. Ibogaine is the principal alkaloid extracted from the bark. It’s the form used in most clinical and semi-clinical addiction-recovery settings, particularly for opioid dependence. The science here is genuinely interesting: ibogaine appears to reset certain neural pathways involved in craving and withdrawal, and many people who go through a single session report that the physical pull of opioids is dramatically reduced afterward. That’s not marketing. That’s what shows up in interviews with participants and in the small body of clinical research that exists. The trade-off is that ibogaine is cardiotoxic in a way most psychedelics are not. It can affect heart rhythm, and people have died from it — almost always when proper medical screening was skipped. This is the single most important fact about ibogaine, and any retreat that doesn’t require an EKG, bloodwork, and a serious medical questionnaire before accepting you is a retreat you should walk away from. Most ayahuasca ceremonies run four to six hours. An iboga session runs anywhere from twenty to thirty-six. You don’t sleep. You don’t move much. You lie on a mat or a low bed in a quiet, dim room, and the medicine takes you somewhere very specific. People describe the early hours as a kind of buzzing, with a high-pitched ringing in the ears and a sense that gravity has doubled. Then the visions start — but not the kaleidoscopic geometry of mushrooms or the spirit-realm of ayahuasca. Iboga visions tend to be cinematic and biographical. Old memories. Faces of people you wronged. Decisions you made at nineteen that you’ve been pretending not to think about. It plays them back without commentary, and you watch. One person I interviewed described it as “sitting through a documentary about myself, produced by someone who has access to every file.” That’s about right. The medicine doesn’t shout. It doesn’t need to. It just shows you what’s there, and lets you draw your own conclusions. The physical side is no joke either. Nausea is common. Ataxia — loss of coordination — is universal; you genuinely cannot walk. Most people don’t want to. You stay lying down, eyes closed, for the entire experience, with a facilitator nearby monitoring vital signs and occasionally bringing water. The population at iboga retreats skews different than at ayahuasca centers. You’ll meet fewer wellness tourists and more people who have run out of other options. In rough strokes: What unites them is a particular kind of seriousness. Iboga isn’t a weekend. It’s closer to elective surgery on your psyche, and the people who choose it tend to know that going in. This is the use case that gets the most attention, and rightly so. For opioid dependence specifically, ibogaine appears to interrupt withdrawal in a way nothing else really does. Participants describe coming out of a session no longer feeling the physical craving that had defined their daily life for years. The window this opens — usually a few weeks to a few months — is when the real work happens. The medicine doesn’t do the work for you. It makes the work possible. Recovery rates vary wildly depending on what happens after the session. Retreats that send you home with no follow-up have poor long-term outcomes. Retreats that integrate ibogaine into a longer program — aftercare calls, therapy, sober community, sometimes a follow-up booster session — show much better numbers. The choice of retreat matters more than almost anything else. It’s also worth being honest: ibogaine isn’t magic. Some people relapse. Some find it doesn’t take. Some have profound experiences that don’t translate into behavior change. Psychedelic-assisted recovery is a tool, not a cure, and any retreat that promises a cure is misrepresenting what they can offer. This is the section to read twice. Iboga and ibogaine retreats vary enormously in quality, and the consequences of choosing badly are higher than with other plant medicines. Cost varies. A serious ibogaine-for-addiction retreat with proper medical infrastructure typically runs between five and ten thousand dollars for a week or two. Traditional Bwiti ceremonies in Africa can be less expensive but require considerably more cultural adaptation. Free or very cheap iboga is almost always a warning sign. Iboga rewards preparation. In the weeks before a session, most retreats ask you to taper off pharmaceuticals (under medical supervision), eat clean, abstain from alcohol and other substances, and start journaling about what you’re bringing to the medicine. The dieta is less elaborate than ayahuasca’s, but the principle is the same: arrive empty so the medicine has room to work. Mentally, the best preparation is honesty. Sit down before you go and write — actually write, on paper — what you want to look at. The patterns you’re tired of. The fears you’ve been avoiding. Iboga will likely show you all of it anyway, but going in with your eyes already open changes the quality of the experience. Afterward, expect to feel scoured. Many people describe a few weeks of unusual clarity, followed by the slow return of regular life. What you do with that clarity window is the whole game. Therapists who specialize in psychedelic integration are worth their weight in gold during this period. If you’ve read this far, you’re probably not casually curious — you’re weighing a real decision. For readers who want to take this further, a range of vetted ibogaine and iboga retreats can be browsed on our marketplace here. Whatever you decide, decide slowly, ask hard questions, and choose the people running the ceremony as carefully as you’d choose a surgeon. With this medicine, that’s not an exaggeration.
Psilocybin Therapy in Oregon: What Legal Access Actually Looks Like
A few years back, the idea of legally sitting with psilocybin mushrooms — in a licensed space, with a trained facilitator, without breaking any laws — sounded like wishful thinking. Then Oregon happened. In November 2020, voters there passed Measure 109, and the state became the first in the U.S. to create a regulated framework for supervised psilocybin use. The rollout has been slow, messy, and fascinating. And if you're someone weighing whether psychedelics might help with depression, trauma, or just a stuck patch of life, what's unfolded in Oregon matters. This isn't a political post. It's a practical one. I want to walk through what Oregon actually legalized, how it fits into the broader psychedelic renaissance, where it leaves people who can't fly to Portland, and what to keep in mind if you're considering plant medicine or psilocybin in a retreat setting. There's a lot of hype out there. The reality is more interesting — and more nuanced — than the headlines suggest. Here's the short version. Measure 109 didn't make psilocybin legal in the way alcohol or cannabis is legal in some states. You can't walk into a dispensary and buy dried mushrooms. You can't grow them at home for personal use without risk. What the measure created was a tightly controlled service model: licensed facilitators, licensed service centers, and clients who go through a preparation session, a dosing session, and an integration session — all on-site, all supervised. You don't need a diagnosis to participate. That's a meaningful detail. Unlike most clinical trials, where you have to qualify with treatment-resistant depression or end-of-life anxiety, Oregon's framework treats psilocybin services as a wellness offering open to adults. Whether that's a feature or a bug depends on who you ask. The state's Psilocybin Services program took its time to write the rules. The first licensed service centers opened in 2023, and as of 2026 there's a working — if still small — network of providers across the state. Prices for a full session run from about $1,500 to $3,500, sometimes more, which is a real barrier and one of the loudest criticisms from advocates who pushed for decriminalization instead of (or alongside) legalization. Oregon didn't happen in a vacuum. For years, researchers at Johns Hopkins, NYU, Imperial College London, and elsewhere have been publishing studies showing that psilocybin — given in a supportive setting, with proper preparation — can produce striking reductions in depression and anxiety, including in people who haven't responded to conventional treatment. The cancer-patient studies got the most press, but the work on major depression and on alcohol-use disorder has been just as compelling. That research is what cracked the door open. Decriminalization measures in Denver, Oakland, Santa Cruz, Ann Arbor, and a growing list of other cities pushed it open further. Then Oregon legalized supervised access. Colorado followed with Proposition 122 in 2022, which created its own regulated framework plus broader decriminalization of several plant medicines, including DMT and mescaline. The picture across the U.S. is now a patchwork. Federally, psilocybin remains a Schedule I substance. State by state, city by city, the rules shift. If you're researching options, the legal landscape where you live is worth checking carefully — not because anyone's likely to kick down your door, but because where the law sits affects which providers operate openly, what kind of training they've had, and what recourse you have if something goes wrong. People imagine a lot of things when they hear “legal mushroom therapy.” The reality is quieter than the imagination. A typical session at an Oregon service center looks something like this: It's not a party. It's not a quick fix. People who walk in expecting fireworks sometimes leave underwhelmed; people who walk in with humility and a real question often leave changed. Your experience depends on dose, set, setting, and frankly your nervous system on the day. The medicine doesn't perform on demand. If you're researching psychedelic options seriously, you've probably noticed that psilocybin isn't the only path on the table. Ayahuasca retreats in Peru, Costa Rica, and increasingly in legally permissive corners of Europe; ibogaine clinics in Mexico for people working through opioid addiction; San Pedro and huachuma ceremonies in the Andes; psilocybin retreats in Jamaica, the Netherlands, and now Oregon. Each tradition carries its own culture, its own risks, its own kind of work. Psilocybin tends to be the gentler doorway. The experience is usually shorter, the body load lighter, the integration arc more manageable for first-timers. Ayahuasca is longer, more physical (yes, the purging is real), and rooted in lineages worth understanding before you sign up. Ibogaine is a different animal entirely — powerful for addiction interruption, but with real cardiac risks that require medical screening. The point isn't to rank them. The point is that the choice should match what you're actually working on. Someone navigating grief and mild depression might find a supervised psilocybin session to be exactly the right size. Someone wrestling with deep generational trauma or long-term substance dependence might be better served by a longer-format plant-medicine retreat with experienced facilitators. There's no universal answer here. Whether you end up booking a psilocybin session in Oregon, an ayahuasca retreat in the Sacred Valley, or something else, the same questions apply. The legal status of a place is one signal. It's not the only signal, and sometimes not the most important one. Cost is real. So is travel. So is the question of how much time you can take afterward to actually let the experience land. A weekend session jammed between two stressful work weeks is a waste of money and an unkindness to yourself. I've sat across from a lot of people considering their first psychedelic retreat. The ones who tend to do well aren't the bravest or the most spiritually fluent. They're the ones who know why they're going. Not in a grand way — just specifically. “I want to look at what happened with my father.” “I want to know if I can stop drinking.” “I've been depressed for three years and nothing has moved.” A clear question makes for clearer work. The ones who struggle are usually running from something rather than toward something, or they've heard psilocybin called a miracle and they want the miracle. The medicine doesn't reward that posture. It tends to show people exactly what they've been avoiding, which is rarely comfortable and almost always useful in the long run. Oregon's experiment is still young. The price point will likely come down as more centers open and competition grows. The model itself — supervised, integrated, deliberately slow — is probably closer to what responsible psychedelic care looks like than either the underground or the pharma-clinical-trial extremes. Whether you go that route, choose a traditional ayahuasca retreat abroad, or stay home and read a few more books before deciding, the honest move is the same: get specific about what you want, get honest about your medical realities, and don't outsource the decision to a marketing brochure. If something here is sitting with you and you want to look at concrete options, a curated range of psilocybin and plant-medicine retreats can be browsed on our marketplace here. Take your time with it. The retreat will still be there next month, and the question of whether you're ready is worth more than a quick yes.
Dreaming of a Psychedelic Retreat?
We have the best deals and offers from thousands of organizers all over the world! Get them into your mailbox every week!
We value your privacy. Your email address will never be shared or published.
